Analyst Price Target is $33.00
▲ +92.53% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Assembly Biosciences in the last 3 months. The average price target is $33.00, with a high forecast of $35.00 and a low forecast of $31.00. The average price target represents a 92.53% upside from the last price of $17.14.
Current Consensus is
Moderate Buy
The current consensus among 3 contributing investment analysts is to moderate buy stock in Assembly Biosciences. This rating has held steady since August 2024, when it changed from a Hold consensus rating.
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial. The company also develops ABI-4334, a next-generation capsid assembly modulator, which is in Phase 1b clinical trial for the treatment of hepatitis B virus (HBV). In addition, it develops an oral non-nucleoside polymerase inhibitor targeting transplant-related herpesviruses; and a small molecule interferon-a receptor agonist targeting HBV and HDV. The company has collaboration agreements with Gilead Sciences, Inc. and BeiGene, Ltd. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
Read More
